Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
Open Access
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 6 (1), 1-9
- https://doi.org/10.1038/s41541-021-00295-7
Abstract
Avian influenza A(H7N9) epidemics have a fatality rate of approximately 40%. Previous studies reported that low pathogenic avian influenza (LPAI)-derived candidate vaccine viruses (CVVs) are poorly immunogenic. Here, we assess the immunogenicity and efficacy of a highly pathogenic avian influenza (HPAI) A/Guangdong/17SF003/2016 (GD/16)-extracted hemagglutinin (eHA) vaccine. GD/16 eHA induces robust H7-specific antibody responses in mice with a marked adjuvant antigen-sparing effect. Mice immunized with adjuvanted GD/16 eHA are protected from the lethal LPAI and HPAI H7N9 challenges, in stark contrast to low antibody titers and high mortality in mice receiving adjuvanted LPAI H7 eHAs. The protection correlates well with the magnitude of the H7-specific antibody response (IgG and microneutralization) or HA group 2 stem-specific IgG. Inclusion of adjuvanted GD/16 eHA in heterologous prime-boost improves the immunogenicity and protection of LPAI H7 HAs in mice. Our findings support the inclusion of GD/16-derived CVV in the pandemic preparedness vaccine stockpile.Keywords
Funding Information
- U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (IAA# 750118PR0600016)
This publication has 47 references indexed in Scilit:
- Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humansnpj Vaccines, 2020
- Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in MiceJournal of Virology, 2019
- Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in HumansmSphere, 2017
- The immune correlates of protection for an avian influenza H5N1 vaccine in the ferret model using oil-in-water adjuvantsScientific Reports, 2017
- Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 AdjuvantJAMA, 2014
- Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in ChinaThe New England Journal of Medicine, 2014
- Cooperativity Between CD8+ T Cells, Non-Neutralizing Antibodies, and Alveolar Macrophages Is Important for Heterosubtypic Influenza Virus ImmunityPLoS Pathogens, 2013
- Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in HumansPLOS ONE, 2012
- Revisiting the 1976 "Swine Flu" Vaccine Clinical Trials: Cross-reactive Hemagglutinin and Neuraminidase Antibodies and Their Role in Protection Against the 2009 H1N1 Pandemic Virus in MiceClinical Infectious Diseases, 2011
- Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza VirusJournal of Virology, 2008